CPRX vs. PCVX, SRPT, QGEN, ASND, ROIV, RVMD, LEGN, BBIO, AXSM, and BPMC
Should you be buying Catalyst Pharmaceuticals stock or one of its competitors? The main competitors of Catalyst Pharmaceuticals include Vaxcyte (PCVX), Sarepta Therapeutics (SRPT), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Legend Biotech (LEGN), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry.
Catalyst Pharmaceuticals vs.
Catalyst Pharmaceuticals (NASDAQ:CPRX) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.
In the previous week, Vaxcyte had 3 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 7 mentions for Vaxcyte and 4 mentions for Catalyst Pharmaceuticals. Vaxcyte's average media sentiment score of 1.08 beat Catalyst Pharmaceuticals' score of 0.65 indicating that Vaxcyte is being referred to more favorably in the news media.
Catalyst Pharmaceuticals presently has a consensus price target of $32.25, indicating a potential upside of 49.72%. Vaxcyte has a consensus price target of $127.71, indicating a potential upside of 58.49%. Given Vaxcyte's higher probable upside, analysts plainly believe Vaxcyte is more favorable than Catalyst Pharmaceuticals.
Catalyst Pharmaceuticals received 454 more outperform votes than Vaxcyte when rated by MarketBeat users. However, 75.41% of users gave Vaxcyte an outperform vote while only 74.96% of users gave Catalyst Pharmaceuticals an outperform vote.
Catalyst Pharmaceuticals has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 11.0% of Catalyst Pharmaceuticals shares are held by insiders. Comparatively, 3.1% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Catalyst Pharmaceuticals has a net margin of 31.01% compared to Vaxcyte's net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 40.79% beat Vaxcyte's return on equity.
Catalyst Pharmaceuticals has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.
Summary
Catalyst Pharmaceuticals beats Vaxcyte on 11 of the 17 factors compared between the two stocks.
Get Catalyst Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Catalyst Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CPRX) was last updated on 2/21/2025 by MarketBeat.com Staff
Free CPRX Stock Alerts